United Therapeutics Corporation

UTHR Healthcare Drug Manufacturers Specialty & Generic

United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.

Revenue
+4.13%
EPS
−21.7%
Free cash flow
−63.7%

Quarter to September 2026, against a year earlier

565.19 0.53 −0.09%
Market cap
$24.3B
P/E
19.7×
Fwd P/E
22.5×
Dividend yield
—
F-score
8/9
Altman Z
19.55
Beneish M
−2.26
Dividend safety
n/a

United Therapeutics Corporation 10-Q filed May 6, 2026

Fiscal Q1 2026 · Period ended Mar 31, 2026 · Filed · accepted 6:30 AM ET · Document on sec.gov · Filing index

Nothing in this filing raised a red flag. The document itself is on sec.gov.

Read the filing on sec.gov